Effect of oral administration of protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on the growth of 3-methylcholanthrene-induced carcinoma in mice.
Oral administration of a synthetic protease inhibitor. [N,N-dimethylcarbamoyl-methyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate, was used to challenge 3-methylcholanthrene-induced carcinoma. This drug was administered 3 times daily via a stomach tube at doses of 12.5, 25 and 50 mg/kg in 33 mice harboring solid tumors. Oral administration of more than 50.0 mg/kg of this protease inhibitor significantly inhibited tumor growth and prolonged the survival time of cancer-harboring animals (P les than 0.05). These results indicate that oral administration of an inhibitor of kinin-forming protease has an antitumor effect on malignant tumors.
D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced / Q000188:drug therapy*; D002455:Cell Division / Q000187:drug effects; D004952:Esters; D005260:Female; D016670:Gabexate / Q000031:analogs & derivatives*; D006146:Guanidines / Q000627:therapeutic use*; D008748:Methylcholanthrene; D051379:Mice; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000139:chemically induced / Q000188:drug therapy*
D004952:Esters; D006146:Guanidines; D011480:Protease Inhibitors; C034532:camostat; D016670:Gabexate; D008748:Methylcholanthrene